AMED vs. DVA, CHE, CRVL, MD, AMN, CCRN, LH, DGX, EHC, and ELAN
Should you be buying Amedisys stock or one of its competitors? The main competitors of Amedisys include DaVita (DVA), Chemed (CHE), CorVel (CRVL), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), Labcorp (LH), Quest Diagnostics (DGX), Encompass Health (EHC), and Elanco Animal Health (ELAN).
Amedisys vs. Its Competitors
Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.
DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.
Amedisys has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.
94.4% of Amedisys shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 2.1% of Amedisys shares are held by insiders. Comparatively, 2.0% of DaVita shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, DaVita had 2 more articles in the media than Amedisys. MarketBeat recorded 9 mentions for DaVita and 7 mentions for Amedisys. DaVita's average media sentiment score of 1.24 beat Amedisys' score of 0.67 indicating that DaVita is being referred to more favorably in the news media.
DaVita has a net margin of 6.63% compared to Amedisys' net margin of 3.79%. DaVita's return on equity of 176.11% beat Amedisys' return on equity.
Amedisys currently has a consensus target price of $100.75, suggesting a potential upside of 4.99%. DaVita has a consensus target price of $164.50, suggesting a potential upside of 15.28%. Given DaVita's higher probable upside, analysts clearly believe DaVita is more favorable than Amedisys.
Summary
DaVita beats Amedisys on 9 of the 15 factors compared between the two stocks.
Get Amedisys News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amedisys Competitors List
Related Companies and Tools
This page (NASDAQ:AMED) was last updated on 7/3/2025 by MarketBeat.com Staff
Free AMED Stock Alerts